Biocatalytic Platform Eliminates Toxic Precursors to Deliver Single-Phase Semiconductor Quantum Dots

This technology uses an artificially designed protein to catalyze the green, controlled synthesis of semiconductor quantum dots in water, enabling precise control over size and chirality for biocompatible nanomaterial applications.

Background

Quantum dots are an emerging technology with applications in electronics, quantum computing, and biology research. Several methods exist for manufacturing quantum dots, varying in efficacy and end product. Most manufacturing processes are contaminating processes that often utilize heavy metals. For bio‐compatible quantum dots, traditional synthesis methods can’t be used as they rely on toxic precursors that are difficult or impossible to remove.

Technology

Researchers at Princeton University’s Department of Chemistry have developed a new method for producing metal chalcogenide semiconductor quantum dots using synthetic *de novo *proteins. These engineered proteins avoid many of the drawbacks associated with natural proteins such as instability, resistance to modification, and difficulty of preparation and isolation. The reaction relies on a common cofactor, and catalyzes the reactions with H₂S as a byproduct. H₂S can be separated for other commercial uses. The proteins can be easily tuned and modified to improve their performance. The quantum dots have optical properties consistent with other methods for producing quantum dots. The material properties and physical sizes of these quantum dots corroborate the formation of nanocrystals in solutions. This is the first demonstration that *de novo *proteins can be used to catalyze the synthesis of semiconductor quantum dots.

The quantum dots were examined using absorbance and fluorescence spectroscopy and further characterized using high‐angle annular dark‐field scanning transmission electron microscopy.

Benefits

  • Eco-Friendly and Biocompatible Synthesis: Enables the production of quantum dots under ambient, non-toxic, and aqueous conditions, eliminating the need for high temperatures and harsh organic solvents used in traditional methods.
  • High Purity and Single-Phase Quality: Produces highly stable, single-phase (zinc blende) nanocrystals, overcoming the mixed-phase limitations typically associated with natural enzyme-mediated biomineralization.
  • Precise Size and Growth Control: Offers highly tunable nanocrystal size and growth kinetics by simply adjusting the incubation time and the concentrations of the protein and PLP cofactor.
  • Chirality Customization: Allows for the creation of chiral quantum dots by selecting either L- or D-cysteine substrates, successfully transferring the ligand’s chirality directly to the inorganic core.
  • Stable and Customizable Catalyst: Utilizes an artificially designed de novo protein that is highly stable and easily adaptable through directed evolution or rational design to produce other metal chalcogenide quantum dots (e.g., PbS or ZnS).
  • Controlled Dispersion and Byproduct Utility: Features slow catalytic kinetics that prevent uncontrolled bulk precipitation, ensuring stable nanocrystal dispersion, while allowing excess hydrogen sulfide byproduct to be captured for secondary chemical processes.

Applications

  • Biocompatible medical imaging agents
  • Eco-friendly quantum dot displays
  • Remediation of metal‐bearing waste stream
  • Productions of H₂S, a useful byproduct
  • Green photovoltaic solar cells

Additional info

This biomineralization method synthesizes single-phase zinc blende semiconductor quantum dots using an artificial *de novo* protein. The PLP-bound protein catalyzes the desulfurization of L- or D-cysteine, generating hydrogen sulfide to react with metal salts in a pH 6–8.5 buffer. Adjusting protein and PLP concentrations controls nanocrystal size (1.47–3 nm), while the cysteine enantiomer dictates quantum dot chirality.